These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis. Tseng AS, Kunze KL, Lee JZ, Amin M, Neville MR, Almader-Douglas D, Killu AM, Madhavan M, Cha YM, Asirvatham SJ, Friedman PA, Gersh BJ, Mulpuru SK. Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582 [Abstract] [Full Text] [Related]
5. In heart failure with reduced ejection fraction patients' left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blockers: results from a retrospective cohort study. De Vecchis R, Paccone A, Di Maio M. J Cardiovasc Med (Hagerstown); 2019 Dec; 20(12):857-858. PubMed ID: 31460889 [No Abstract] [Full Text] [Related]
6. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial. Florea VG, Rector TS, Anand IS, Cohn JN. Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037 [Abstract] [Full Text] [Related]
7. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE, REVERT Study Group. Circulation; 2007 Jul 03; 116(1):49-56. PubMed ID: 17576868 [Abstract] [Full Text] [Related]
8. Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Oghlakian GO, Sipahi I, Fang JC. Mayo Clin Proc; 2011 Jun 03; 86(6):531-9. PubMed ID: 21576513 [Abstract] [Full Text] [Related]
9. Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. Pokharel Y, Wei J, Hira RS, Kalra A, Shore S, Kerkar PG, Kumar G, Risch S, Vicera V, Oetgen WJ, Deswal A, Turakhia MP, Glusenkamp N, Virani SS. Clin Cardiol; 2016 Mar 03; 39(3):145-9. PubMed ID: 26880649 [Abstract] [Full Text] [Related]
17. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH. JACC Cardiovasc Imaging; 2011 Dec 03; 4(12):1239-49. PubMed ID: 22172779 [Abstract] [Full Text] [Related]
20. Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. Pandey A, Garg S, Matulevicius SA, Shah AM, Garg J, Drazner MH, Amin A, Berry JD, Marwick TH, Marso SP, de Lemos JA, Kumbhani DJ. J Am Heart Assoc; 2015 Oct 12; 4(10):e002137. PubMed ID: 26459931 [Abstract] [Full Text] [Related] Page: [Next] [New Search]